All In Biotech

Drug Trial Radar · NCT06262139

Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients

An Open-label Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent (MT218) in Prostate Cancer Patients

Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Jul 25, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Songqi GaoIndustry
Sponsor type
Industry
Collaborators
Emory University
First posted
Feb 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 1b open label, dose-escalating investigation study is to evaluate the dose dependent initial efficacy of the use of MT218 injection for biomarker targeted MR molecular imaging (MRMI) of prostate cancer in patients scheduled for radical prostatectomy.

Conditions

  • MRI Scan

Interventions

  • MT218 injectionDrug

    a targeted magnetic resonance imaging contrast agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Detection of aggressive prostate cancer (Gleason score 8 to 10) using peptide based MRI contrast agent (MT218) with comparing the previous clinical mpMRI using the clinical standard MRI contrast agent and PSMA-PET/CTTime frame: up to 3 days after injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emory University

    Atlanta, Georgia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.